Scribe Therapeutics Posts $9.9 Million Q3 Net Loss, Reports $174.2 Million in Cash

Scribe Therapeutics reported a third-quarter 2026 net loss of $9.9 million, compared with net income of $1.5 million in the year-ago quarter. Collaboration revenue was $1.6 million, and cash, cash equivalents and marketable securities totaled $174.2 million at September 30. The company said its cas…